Arcutis Biotherapeutics(ARQT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, net product revenues reached $127.5 million, reflecting an 84% year-over-year growth and a 29% sequential growth from Q3 2025 [15][49] - For the full year 2025, net product revenues totaled $372.1 million, a 123% increase compared to 2024, driven by increasing demand for ZORYVE products [53][56] - The company achieved positive cash flow in Q4 2025, with cash and marketable securities at $221.3 million as of December 31, 2025 [52] Business Line Data and Key Metrics Changes - ZORYVE's net product revenues grew to $372 million in 2025, a 123% increase year-over-year, driven by a doubling in total prescription volume [5][53] - In Q4 2025, ZORYVE generated $127.5 million in revenue, with a 19% increase in prescription volume contributing to this growth [15][49] Market Data and Key Metrics Changes - ZORYVE holds approximately 45% of the branded non-steroidal topical segment, which is experiencing a shift away from topical corticosteroids [5][21] - The branded non-steroidal topical segment now accounts for 7% of total topical prescriptions, indicating a meaningful shift in treatment paradigms [21][23] Company Strategy and Development Direction - The company is focused on a three-pillar corporate strategy aimed at sustaining near and long-term growth, which includes expanding ZORYVE's market presence and pursuing new indications [11][12] - The expansion of the dermatology specialty sales force by 20% aims to increase engagement with mid-decile prescribers and enhance ZORYVE's market penetration [24][26] Management's Comments on Operating Environment and Future Outlook - Management raised the 2026 full-year net product revenue guidance to $480 million-$495 million, reflecting strong momentum for ZORYVE [13][56] - The company remains confident in maintaining positive cash flow throughout 2026 while continuing to invest in ZORYVE's growth and pipeline [14][52] Other Important Information - The company submitted an sNDA for ZORYVE Cream 0.3% for psoriasis in children ages 2 to 5, with a target action date of June 29, 2026 [8][41] - Positive top-line results from the INTEGUMENT-INFANT trial for ZORYVE Cream 0.05% in infants with atopic dermatitis were reported, showing significant improvement in patients [35][38] Q&A Session Summary Question: Update on market dynamics and access for ZORYVE - Management confirmed that ZORYVE has achieved significant access across commercial, Medicare, and Medicaid, with over 80% of patients insured by commercial insurance having access [63][64] Question: Sales growth trends for different SKUs - Management indicated that there was meaningful growth across all SKUs, particularly for ZORYVE foam, and anticipates continued growth throughout 2026 [74]